A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
Clinical trial NCT02091999 · COMPLETED
Trial details
- NCT number
- NCT02091999
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-05-14
- Primary completion
- 2022-12-07
- Enrollment
- 213
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.